bluebird bio Inc
NASDAQ:BLUE

Watchlist Manager
bluebird bio Inc Logo
bluebird bio Inc
NASDAQ:BLUE
Watchlist
Price: 4.97 USD
Market Cap: 48.7m USD

bluebird bio Inc
Investor Relations

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 518 full-time employees. The company went IPO on 2013-06-19. The firm is principally focused on researching, developing and commercializing gene therapies for genetic diseases. The Company’s programs in genetic diseases include betibeglogene autotemcel (beti-cel) as a treatment for transfusion-dependent B-thalassemia (TDT); LentiGlobin product candidate as a treatment for sickle cell disease (SCD), and elivaldogene autotemcel (eli-cel) as a treatment for cerebral adrenoleukodystrophy (CALD). The company develops LentiGlobin gene therapy for patients with SCD, a hereditary blood disorder resulting from a mutation in the b-globin gene that causes polymerization of hemoglobin proteins, resulting in abnormal red blood cell function. The beti-cel is marketed as ZYNTEGLO for the treatment of adult and adolescent patients with TDT in the European Union. Its product candidate also include SKYSONA for the treatment of patients with CALD in the European Union, Iceland, Liechtenstein and Norway.

Show more
Loading

Earnings Calls

2024 Q3
Nov 14, 2024
Show Transcript
Previous
Next
bluebird bio anticipates revenue growth and cost reduction amid strong demand.
2024 Q3
Nov 14, 2024

In the third quarter, bluebird bio reported a revenue decline to $10.6 million but expects a rebound to at least $25 million in the fourth quarter due to increased patient infusions. Notably, the company has confirmed the effectiveness of its LYFGENIA therapy, which had its first revenue recognized. The firm plans a 20% reduction in cash operating expenses by 2025, aiming for cash flow breakeven in the second half of that year. With 30 patients scheduled for treatment in 2025, bluebird’s manufacturing capability appears robust, and access to therapies has improved significantly through insurance approvals.

Show Full Analysis

Management

Mr. Andrew Obenshain
President, CEO & Director
No Bio Available
Mr. Thomas J. Klima
Chief Commercial Officer & COO
No Bio Available
Mr. Richard A. Colvin M.D., Ph.D.
Chief Medical Officer
No Bio Available
Mr. Oliver James Sterling III
CFO & Principal Accounting Officer
No Bio Available
Mr. Joseph D. Vittiglio Esq., J.D.
Chief Legal & Business Officer and Secretary
No Bio Available
Jess Rowlands
Head of Corporate Communications
No Bio Available
Ms. Andrea Walton
Chief People Officer
No Bio Available
Mr. Kasra Kasraian
Senior Vice President of Technical Development & Operations
No Bio Available
Mr. Scott Shoemaker
Senior Vice President of Quality
No Bio Available
Ms. Sarah Alspach
Senior Vice President of External Affairs
No Bio Available

Contacts

Address
MASSACHUSETTS
Cambridge
60 Binney St
Contacts
+13394999300.0
www.bluebirdbio.com